Aptorum Group Limited: Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from

Related Keywords

Singapore ,Clark Cheng ,Ghislaine Gasparetto ,Aptorum Group Form ,Aptorum Group Or ,Technologies Pte Ltd ,Singapore Agency For Science ,Actifin Financial Communications Europe ,Redchip Financial Communications United States ,Daptorum Group ,Aptorum Group Limited Nasdaq ,Regulatory News ,Group Limited ,Euronext Paris ,Chief Medical Officer ,Executive Director ,Accelerate Technologies Pte Ltd ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Financial Communications United States ,Financial Communications Europe ,Aptorum ,Group ,Imited ,Updates ,Data ,Rom ,Ompleted ,Hase ,Linical ,Trial ,Fact ,Targeting ,Neuroblastoma ,